Impact of TRIM5α and TRIM22 Genes Expression on the Clinical Course of Coronavirus Disease 2019
Copyright © 2022 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved..
OBJECTIVE: The innate immune response in humans involves a wide variety of factors, including the tripartite motif-containing 5α (TRIM5α) and 22 (TRIM22) as a cluster of genes on chromosome 11 that have exhibited antiviral activity in several viral infections. We analyzed the correlation of the expression of TRIM5α and TRIM22 with the severity of Coronavirus Disease 2019 (COVID-19) in blood samples of 330 patients, divided into two groups of severe and mild disease, versus the healthy individuals who never had contact with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
METHODS: The transcription level of TRIM5α and TRIM22 was determined by quantitative real-time polymerase chain reaction (qPCR). The laboratory values were collected from the patients' records.
RESULTS: The expression of both genes was significantly lower in the severe group containing the hospitalized patients than in both the mild group and the control group. However, in the mild group, TRIM22 expression was significantly higher (p <0.0001) than in the control group while TRIM5α expression was not significantly different between these two groups. We found a relationship between the cycle threshold (Ct) value of patients and the expression of the aforementioned genes.
CONCLUSION: The results of our study indicated that lower Ct values or higher RNA viral load might be associated with the downregulation of TRIM5α and TRIM22 and the severity of COVID-19. Additional studies are needed to confirm the results of this study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Archives of medical research - 54(2023), 2 vom: 13. Feb., Seite 105-112 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tavakoli, Rezvan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.03.2023 Date Revised 14.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.arcmed.2022.12.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351324860 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351324860 | ||
| 003 | DE-627 | ||
| 005 | 20231226051106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.arcmed.2022.12.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351324860 | ||
| 035 | |a (NLM)36621405 | ||
| 035 | |a (PII)S0188-4409(22)00187-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tavakoli, Rezvan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of TRIM5α and TRIM22 Genes Expression on the Clinical Course of Coronavirus Disease 2019 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2023 | ||
| 500 | |a Date Revised 14.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: The innate immune response in humans involves a wide variety of factors, including the tripartite motif-containing 5α (TRIM5α) and 22 (TRIM22) as a cluster of genes on chromosome 11 that have exhibited antiviral activity in several viral infections. We analyzed the correlation of the expression of TRIM5α and TRIM22 with the severity of Coronavirus Disease 2019 (COVID-19) in blood samples of 330 patients, divided into two groups of severe and mild disease, versus the healthy individuals who never had contact with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | ||
| 520 | |a METHODS: The transcription level of TRIM5α and TRIM22 was determined by quantitative real-time polymerase chain reaction (qPCR). The laboratory values were collected from the patients' records | ||
| 520 | |a RESULTS: The expression of both genes was significantly lower in the severe group containing the hospitalized patients than in both the mild group and the control group. However, in the mild group, TRIM22 expression was significantly higher (p <0.0001) than in the control group while TRIM5α expression was not significantly different between these two groups. We found a relationship between the cycle threshold (Ct) value of patients and the expression of the aforementioned genes | ||
| 520 | |a CONCLUSION: The results of our study indicated that lower Ct values or higher RNA viral load might be associated with the downregulation of TRIM5α and TRIM22 and the severity of COVID-19. Additional studies are needed to confirm the results of this study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Coronavirus disease 2019 | |
| 650 | 4 | |a Tripartite motif-containing 22 | |
| 650 | 4 | |a Tripartite motif-containing 5α | |
| 650 | 4 | |a cycle threshold value | |
| 650 | 4 | |a mild infection | |
| 650 | 4 | |a severe infection | |
| 650 | 7 | |a Repressor Proteins |2 NLM | |
| 650 | 7 | |a Tripartite Motif Proteins |2 NLM | |
| 650 | 7 | |a TRIM22 protein, human |2 NLM | |
| 650 | 7 | |a Minor Histocompatibility Antigens |2 NLM | |
| 700 | 1 | |a Rahimi, Pooneh |e verfasserin |4 aut | |
| 700 | 1 | |a Hamidi-Fard, Mojtaba |e verfasserin |4 aut | |
| 700 | 1 | |a Eybpoosh, Sana |e verfasserin |4 aut | |
| 700 | 1 | |a Doroud, Delaram |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghi, Seyed Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Zaheri Birgani, Mohammadali |e verfasserin |4 aut | |
| 700 | 1 | |a Aghasadeghi, Mohammadreza |e verfasserin |4 aut | |
| 700 | 1 | |a Fateh, Abolfazl |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of medical research |d 1996 |g 54(2023), 2 vom: 13. Feb., Seite 105-112 |w (DE-627)NLM012656291 |x 1873-5487 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2023 |g number:2 |g day:13 |g month:02 |g pages:105-112 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arcmed.2022.12.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2023 |e 2 |b 13 |c 02 |h 105-112 | ||